SI3518960T1 - Odmerni režim za PTH spojino z nadzorovanim sproščanjem - Google Patents

Odmerni režim za PTH spojino z nadzorovanim sproščanjem

Info

Publication number
SI3518960T1
SI3518960T1 SI201731422T SI201731422T SI3518960T1 SI 3518960 T1 SI3518960 T1 SI 3518960T1 SI 201731422 T SI201731422 T SI 201731422T SI 201731422 T SI201731422 T SI 201731422T SI 3518960 T1 SI3518960 T1 SI 3518960T1
Authority
SI
Slovenia
Prior art keywords
controlled
dosage regimen
pth compound
release pth
release
Prior art date
Application number
SI201731422T
Other languages
English (en)
Inventor
Lars Holten-Andersen
Kennett Sprogoe
David Brian Karpf
Original Assignee
Ascendis Pharma Bone Diseases A/S,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases A/S, filed Critical Ascendis Pharma Bone Diseases A/S,
Publication of SI3518960T1 publication Critical patent/SI3518960T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201731422T 2016-09-29 2017-09-28 Odmerni režim za PTH spojino z nadzorovanim sproščanjem SI3518960T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16191451 2016-09-29
EP17155843 2017-02-13
PCT/EP2017/074592 WO2018060310A1 (en) 2016-09-29 2017-09-28 Dosage regimen for a controlled-release pth compound
EP17781425.8A EP3518960B1 (en) 2016-09-29 2017-09-28 Dosage regimen for a controlled-release pth compound

Publications (1)

Publication Number Publication Date
SI3518960T1 true SI3518960T1 (sl) 2023-11-30

Family

ID=60051488

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731422T SI3518960T1 (sl) 2016-09-29 2017-09-28 Odmerni režim za PTH spojino z nadzorovanim sproščanjem

Country Status (23)

Country Link
US (5) US11590207B2 (sl)
EP (2) EP4275677A3 (sl)
JP (3) JP7197468B2 (sl)
KR (2) KR20240013849A (sl)
CN (2) CN109789189B (sl)
AU (1) AU2017336249B2 (sl)
BR (1) BR112019005533A2 (sl)
CA (1) CA3037442A1 (sl)
DK (1) DK3518960T5 (sl)
ES (1) ES2959995T3 (sl)
FI (1) FI3518960T3 (sl)
HR (1) HRP20231079T1 (sl)
HU (1) HUE063235T2 (sl)
IL (2) IL304086A (sl)
LT (1) LT3518960T (sl)
MX (1) MX2019003181A (sl)
NZ (1) NZ751969A (sl)
PL (1) PL3518960T3 (sl)
RS (1) RS64440B1 (sl)
SG (1) SG11201901576QA (sl)
SI (1) SI3518960T1 (sl)
WO (1) WO2018060310A1 (sl)
ZA (1) ZA201901811B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113972C (en) * 2011-12-14 2023-08-01 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
RU2747316C2 (ru) * 2016-03-01 2021-05-04 Асцендис Фарма Боун Дизизис А/С Пролекарства pth
JP7085535B2 (ja) 2016-09-29 2022-06-16 アセンディス ファーマ ボーン ディジージズ エー／エス ピーク対トラフ比が小さいｐｔｈ化合物
EP4275677A3 (en) * 2016-09-29 2024-01-10 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
US20210196801A1 (en) * 2018-05-18 2021-07-01 Ascendis Pharma Bone Diseases A/S Starting Dose of PTH Conjugates
SG11202107722VA (en) 2019-02-11 2021-08-30 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
CN117586372A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效特立帕肽化合物

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744444A (en) 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1477496A4 (en) 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd PEG BINDING PTH OR PEG BINDING PTH DERIVATIVE
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
ES2512499T3 (es) 2003-04-08 2014-10-24 Yeda Research And Development Co., Ltd. Fármacos pegilados reversibles
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
CA2824093C (en) 2004-03-23 2016-10-25 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
CN1597697A (zh) 2004-07-19 2005-03-23 中国药科大学 一种人的甲状旁腺素1－34肽相关肽－Pro－Pro－[Arg11]]hPTH(1－34)－Pro－Pro
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
EP1799759A1 (en) * 2004-08-30 2007-06-27 Lunamed Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
EP1736059A1 (en) 2005-06-21 2006-12-27 Fuji Oil Europe Structuring granular composition
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN1298386C (zh) 2005-08-31 2007-02-07 上海交通大学 甲状旁腺激素缓释微球的制备方法
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
WO2007106597A2 (en) 2006-03-15 2007-09-20 Alza Corporation Method for the transdermal delivery of parathyroid hormone agents for treating osteopenia
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
PL2084183T3 (pl) * 2006-10-13 2010-10-29 Lilly Co Eli Pegylowane pth jako modulatory receptora pth i ich zastosowania
US8101729B2 (en) * 2007-03-19 2012-01-24 Henry Joseph Niemczyk Pegylated amino acid derivatives and the process to synthesize the same
DK3091075T3 (en) 2007-04-09 2018-07-16 Univ Arkansas FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYRO OIDA HORMON
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
JP2010533202A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
US7633977B2 (en) 2007-08-08 2009-12-15 Wisconsin Alumni Research Foundation Multispectral laser with improved time division multiplexing
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
US8906847B2 (en) 2008-02-01 2014-12-09 Ascendis Pharma A/S Prodrug comprising a drug linker conjugate
LT3050576T (lt) 2008-04-29 2021-07-12 Ascendis Pharma Endocrinology Division A/S Pegiliuoti rekombinantinio žmogaus augimo hormono junginiai
EP2288261A4 (en) 2008-05-23 2013-09-25 Enzon Pharmaceuticals Inc POLYMER SYSTEMS CONTAINING INTRA-CELLULAR RELEASE DISULFID LINKERS FOR THE DISPOSAL OF OLIGONUCLEOTIDES
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
WO2010022171A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Peptidic pth receptor agonists
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
CN102472593A (zh) 2009-07-16 2012-05-23 洛克希德马丁公司 用于换热器的螺旋状管束的配置
JP5738291B2 (ja) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
EP2459225A1 (en) * 2009-07-31 2012-06-06 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
WO2011012723A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
UA108475C2 (uk) * 2009-07-31 2015-05-12 Санофі-Авентіс Дойчланд Гмбх Композиція інсуліну тривалої дії
SI2459220T1 (sl) 2009-07-31 2020-12-31 Ascendis Pharma A/S Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola
US9750890B2 (en) 2009-09-30 2017-09-05 Sanofi-Aventis Deutschland Gmbh Mechanism for a drug delivery device
TW201121601A (en) 2009-09-30 2011-07-01 Sanofi Aventis Deutschland Drive assembly, piston rod, drug delivery device, and use of a spring
US20130053405A1 (en) * 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
AU2010332958B2 (en) 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
EP2519228A4 (en) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
EP2525830B1 (en) * 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US20110229580A1 (en) * 2010-03-22 2011-09-22 Indian Institute of Technology Bombay, School of Biosciences and Bioengineering Compositions and methods for nano-in-micro particles
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN103025164B (zh) 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
CN103025165B (zh) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
CN103002906B (zh) * 2010-05-13 2017-12-29 总医院有限公司 甲状旁腺激素类似物及其应用
PL2571510T3 (pl) 2010-05-21 2019-03-29 Xl-Protein Gmbh Biosyntetyczne polipeptydy prolinowo/alaninowe o strukturze kłębka statystycznego i ich zastosowania
US8865220B2 (en) 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
WO2012002047A1 (ja) 2010-06-30 2012-01-05 Ｎｅｃソフト株式会社 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム
US20120040320A1 (en) * 2010-08-13 2012-02-16 Nadeau Daniel A Injection Simulation Device and Methods Thereof
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
MX2014001496A (es) * 2011-08-12 2014-04-30 Ascendis Pharma As Composicion de liberacion sostenida de prostaciclina.
EP2741782B1 (en) * 2011-08-12 2020-05-06 Ascendis Pharma A/S Protein carrier-linked prodrugs
EP2741744A1 (en) * 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
CN103857413A (zh) 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 载体连接的曲罗尼尔前药
CA2843503C (en) 2011-08-12 2020-12-22 Ulrich Hersel Polymeric hyperbranched carrier-linked prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
SG11201400815TA (en) * 2011-10-12 2014-09-26 Ascendis Pharma Ophthalmology Division As Prevention and treatment of ocular conditions
DE102011116960B3 (de) 2011-10-26 2012-10-25 Stahlbrandschutz Gmbh Dämmschichtbildendes Anstrichmittel
DE102011117182A1 (de) 2011-10-28 2013-05-02 Ruhrpumpen Gmbh Teilstromführung, insbesondere einer Magnetkupplungspumpe
US8883862B2 (en) 2012-01-12 2014-11-11 Kaohsiung Medical University Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US9457096B2 (en) * 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
US9718868B2 (en) 2012-08-28 2017-08-01 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
WO2014056926A1 (en) * 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
NZ706853A (en) * 2012-10-11 2018-04-27 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
RU2682676C2 (ru) * 2012-10-11 2019-03-20 Асцендис Фарма Ас Диагностика, профилактика и лечение болезней суставов
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
JP6290243B2 (ja) * 2012-12-07 2018-03-07 アセンディス ファーマ エー／エス 担体連結プロスタノイドプロドラッグ
GB201303771D0 (en) * 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
US11116849B2 (en) * 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
WO2015031709A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations comprising a peptide and a vasodilatory agent
US10040850B2 (en) * 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag
EP2868326A1 (en) * 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptide inhibitors of TEAD/YAP-TAZ interaction
CA2955569C (en) * 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
SG11201705521YA (en) * 2015-01-09 2017-08-30 Ascendis Pharma Growth Disorders As Cnp prodrugs
AR105319A1 (es) * 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
RU2747316C2 (ru) 2016-03-01 2021-05-04 Асцендис Фарма Боун Дизизис А/С Пролекарства pth
EP4275677A3 (en) 2016-09-29 2024-01-10 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
JP7085535B2 (ja) * 2016-09-29 2022-06-16 アセンディス ファーマ ボーン ディジージズ エー／エス ピーク対トラフ比が小さいｐｔｈ化合物
KR20230066147A (ko) 2016-09-29 2023-05-12 아센디스 파마 그로우쓰 디스오더스 에이/에스 조절 방출 cnp 아고니스트를 사용한 병용 요법
EP3518982A1 (en) 2016-09-29 2019-08-07 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
US20210196801A1 (en) 2018-05-18 2021-07-01 Ascendis Pharma Bone Diseases A/S Starting Dose of PTH Conjugates
SG11202107722VA (en) 2019-02-11 2021-08-30 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
MX2022007371A (es) 2020-01-13 2022-07-12 Ascendis Pharma Bone Diseases As Tratamiento del hipoparatiroidismo.

Also Published As

Publication number Publication date
KR20240013849A (ko) 2024-01-30
SG11201901576QA (en) 2019-03-28
EP4275677A3 (en) 2024-01-10
US20240245755A1 (en) 2024-07-25
KR102627405B1 (ko) 2024-01-18
IL265591A (en) 2019-05-30
RU2019112913A (ru) 2020-10-30
JP2024041859A (ja) 2024-03-27
US11590207B2 (en) 2023-02-28
JP2019535648A (ja) 2019-12-12
US20230381284A1 (en) 2023-11-30
PL3518960T3 (pl) 2023-12-27
US20230248836A1 (en) 2023-08-10
JP7418527B2 (ja) 2024-01-19
BR112019005533A2 (pt) 2019-06-18
CN109789189A (zh) 2019-05-21
DK3518960T5 (da) 2024-09-02
CA3037442A1 (en) 2018-04-05
DK3518960T3 (da) 2023-09-04
CN117838873A (zh) 2024-04-09
FI3518960T3 (fi) 2023-10-04
JP7197468B2 (ja) 2022-12-27
AU2017336249B2 (en) 2024-08-01
HUE063235T2 (hu) 2024-01-28
NZ751969A (en) 2023-04-28
RU2019112913A3 (sl) 2021-01-18
EP3518960A1 (en) 2019-08-07
EP4275677A2 (en) 2023-11-15
IL304086A (en) 2023-08-01
US11890326B2 (en) 2024-02-06
IL265591B1 (en) 2023-08-01
US20230321198A1 (en) 2023-10-12
LT3518960T (lt) 2023-09-11
US11918628B2 (en) 2024-03-05
KR20190062496A (ko) 2019-06-05
US20200023041A1 (en) 2020-01-23
WO2018060310A1 (en) 2018-04-05
MX2019003181A (es) 2019-08-05
ZA201901811B (en) 2019-12-18
CN109789189B (zh) 2024-01-23
EP3518960B1 (en) 2023-07-19
AU2017336249A1 (en) 2019-03-21
JP2023017796A (ja) 2023-02-07
IL265591B2 (en) 2023-12-01
RS64440B1 (sr) 2023-09-29
ES2959995T3 (es) 2024-02-29
HRP20231079T1 (hr) 2023-12-22

Similar Documents

Publication Publication Date Title
ZA201901811B (en) Dosage regimen for a controlled-release pth compound
AU364518S (en) Case for a tablet computer
AU365813S (en) Case for a tablet computer
GB201706327D0 (en) A pharmaceutical compound
ZA201805565B (en) Turret with a zero stop
GB201713653D0 (en) Dosage regimen
AU361966S (en) Follower for a fire arm magazine
GB201603863D0 (en) A workbench
IL252423A0 (en) Ajoan production process
GB201511068D0 (en) A mechanism
GB2559104B (en) Barrier for a bed
HK1209063A1 (en) A device for diffusing a compound
GB2548105B (en) A device for a bicycle
IL266255A (en) New dosage regimen
PT3518960T (pt) Regime de dosagem para um composto de pth de libertação controlada
ZA201800217B (en) Novel dosage regimen tiacumicin compound
PL3322081T3 (pl) Regulator wstępny dla ściemniacza
IL232132A0 (en) Locking mechanism for bicycles
GB201502074D0 (en) A bicycle
MA46343A (fr) Schéma posologique pour un composé de pth à libération contrôlée
GB201617850D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen
GB2545201B (en) A saddle
HUE048566T2 (hu) Gyógyszercsomagolás
GB2546242B (en) A tricycle